Pharmacotherapy for squamous-cell carcinoma of the head and neck.

@article{Papaspyrou2011PharmacotherapyFS,
  title={Pharmacotherapy for squamous-cell carcinoma of the head and neck.},
  author={Giorgos Papaspyrou and Jochen Werner and Andreas Dietz},
  journal={Expert opinion on pharmacotherapy},
  year={2011},
  volume={12 3},
  pages={397-409}
}
INTRODUCTION squamous-cell carcinoma of the head and neck (HNSCC) is one of the most common malignancies, the treatment of which constitutes a therapeutic challenge. AREAS COVERED the purpose of this review is to provide an update on the pharmacotherapy for the treatment of HNSCC focusing mainly on molecular-targeted therapies. An overview of the different novel therapeutic agents that can selectively inhibit signaling pathways and receptors that are involved in the development and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 68 references

Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis [abstract

  • MV Karamouzis, D Friedland, R Johnson
  • J Clin Oncol
  • 2007
Highly Influential
3 Excerpts

inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma

  • Y Baba, Y Kato, cancer Ogawa K. Inostamycin prevents malignant phenotype of
  • Cell Biol Int 2010;34:171-5 Pharmacotherapy for…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…